INDSWFTLAB share price, P/E, ROE & financials

On 6 Nov 2026, Ind-Swift Laboratories was priced at ₹348.20, or 36.1× trailing earnings, against an industry P/E of 28.7×, and the shares are 18% below their 52-week high. Its ROCE of 3.6% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit fell 20% and 3.2% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹3,077 Cr, ranked 52nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 251% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹356.00
Day high: ₹359.45
Day low: ₹343.00
Prev. close: ₹356.75
Volume: 3.5 L

Health check

1 good · 5 to check

ReturnsAhead
+251.1% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 36.1 vs industry 28.7.
GrowthShrinking
Sales −19.7%, profit −3.2% a year over 3 years.
ProfitabilityWeak
ROCE 3.6% vs peer median 17.9%.
Balance sheetStretched
Practically debt-free, Piotroski 3 of 9.
Red flags1 to check
Return on equity is low at 6.1%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹3,077 Cr, #52 of 154 in its industry by size.

Moves with the market

Beta 0.88 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Sep 2026: sales ₹764 Cr · profit ₹85 Cr

Market cap: ₹3,077 Cr; Small cap
P/E: 36.1; Industry 28.7
Price to book: 2.05; Peers 4.99
Dividend yield: 0.00%
ROE: 6.1%; Peers 14.7%
ROCE: 3.6%; Peers 17.9%
Debt to equity: 0.01; Debt ₹21 Cr
EPS (TTM): ₹9.64; Face value ₹10
OPM (TTM): 13.8%; Net margin 11.2%
Sales growth: +51.6%; Latest quarter vs a year ago
Profit growth: +328.3%; Latest quarter vs a year ago
Price to sales: 4.03; EV/EBITDA 24.9

Strengths

Practically debt-free.
Quarterly profit up 328.3% on a year ago.
Quarterly sales up 51.6% on a year ago.

Risks to check

Return on equity is low at 6.1%.

Derived automatically from reported figures. Not a recommendation.

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic,…

Headquarters: Manimajra
Employees: 1,388
Sector: Healthcare
ISIN: INE915B01019
Website: indswiftlabs.com

Price range

52 weeks

₹87.15₹426.60

Today

₹343.00₹359.45

Avg volume (3M): 12.4 L
1-year return: plus 251.1%
From 52-week high: minus 18.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
INDSWFTLABInd-Swift Laboratories	348.20	minus 2.40%	3,077	36.1	2.05	3.6%	6.1%	9.0%	−19.7%	−3.2%	0.00%	plus 251.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
159	151	170	191	240
151	147	149	158	195
7.5	4.2	20.6	33.4	45.5
4.7%	2.8%	12.1%	17.5%	18.9%
11.9	27.6	4.7	7.7	7.6
2	0.7	–	0.7	1.3
7	8.8	8.1	7.6	7.8
–	−5.9	−5.2	−0.2	−0.6
10.3	16.4	12	32.6	43.4
22.2%	41.9%	−26.3%	24.5%	21.3%
8	9.5	15.1	24.7	34.2
0.96	1.13	1.76	2.84	3.92

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −19.7%
Profit CAGR 3Y: −3.2%
ROE: 6.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,207	1,709	562	626
–	+41.6%	minus 67.1%	+11.4%
968	1,386	579	600
239	323	−17.2	25.8
19.8%	18.9%	−3.1%	4.1%
19.1	21.9	75.8	67
86.4	97.8	1.4	0.2
57.4	80.4	24.5	30.6
−27.7	432	225	−11.2
86.5	598	258	50.8
44.7%	9.9%	2.8%	15.2%
47.6	539	250	43.1
–	+1031.9%	minus 53.5%	minus 82.8%
-4.28	91.18	35.21	5.03

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
59.8	67.2	68.7	86.8
622	745	1,104	1,297
862	217	33	17.9
280	432	232	271
1,824	1,460	1,438	1,673
594	231	266	305
8.7	66.5	19	41.9
30.3	110	172	216
23.2	478	464	442
1,168	575	517	669
1,824	1,460	1,438	1,673

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
195	−187	−28.7	−68.2
−13.4	−27.2	−113	−72.7
−186	657	72.4	142
−4.4	443	−69.4	1
−12.8	−73	−64.4	−87.7
182	−260	−93.1	−156

Shareholding pattern

Source: NSE filings

42.9%

promoters

Promoters42.93%
Public57.07%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	42.93%	57.07%	0.00
17 Sep 2026	42.93%	57.07%	0.00
30 Jun 2026	42.93%	57.07%	minus 0.06
31 Mar 2026	42.99%	57.01%	minus 0.07
24 Feb 2026	43.06%	56.94%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you